UTHR — United Therapeutics Corporation price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $584.10
- YTD price return
- +19.88%
- YTD total return
- +19.88%
- Market cap
- 24.9B
- Enterprise value
- 22.8B
- Shares outstanding
- 42.6M
- 52W low
- $455.63
- 52W high
- $614.23
- From 52W high
- -4.91%
- From 52W low
- +28.20%
- 52W range
- 81%$456–$614
- Beta
- 0.56
Volume
- Rel volume
- 0.68×
- 30D volume
- 596.2K
- 30D $ vol
- 339.3M
Insider trading
- Insider net 1W
- −$16.8M
- Insider net 1M
- −$116.9M
- Insider net 3M
- −$344.2M
- Insider net 1Y
- −$1.27B
Form 4 transactions by trade date, as filed; latest on file 2026-11-16.
Fundamentals
- Sales (ttm)
- 3.2B
- Sales/share
- $74.84
- EPS (ttm)
- $26.53
- FCF (ttm)
- 867.2M
- FCF/share
- $20.36
- Book value/share
- $147.36
- Net margin
- 38.61%
- ROE
- 19.61%
- ROA
- 17.50%
- Current ratio
- 4.61
Growth (CAGR, ttm) · 10Y
- Sales
- +1.89%+13.08%+14.01%+7.17%
- Net income
- -3.22%+11.00%+21.63%+5.69%
- FCF
- -22.72%+4.30%+12.22%+6.76%
- Shares
- -1.09%-3.23%-1.11%+0.04%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +0.49%+13.46%+21.75%+5.99%
- Sales/share
- +3.01%+16.85%+15.29%+7.13%
- FCF/share
- -21.87%+7.78%+13.48%+6.72%
- Book value/share
- -3.72%+6.63%+11.63%+13.02%
- Price
- +23.79%+36.63%+23.98%+15.94%
- Total return
- +23.79%+36.63%+23.98%+15.94%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 22.0×
- P/OI (ttm)
- 18.8×
- Fwd P/E
- 16.9×
- P/S (ttm)
- 7.8×
- P/B (mrq)
- 4.0×
- P/FCF (ttm)
- 28.7×
- EV/EBITDA (fy)
- 16.1×
- EV/Sales (ttm)
- 7.2×
- FCF yield (ttm)
- 3.49%
- Buyback yield (realized, 1y)
- 1.09%
- Shareholder yield (realized, 1y)
- 1.09%
- Buyback yield (cash, ttm)
- 8.04%
- Shareholder yield (cash, ttm)
- 8.04%
Vs own 10Y history
- P/E
- 97th
- P/OI
- 93rd
- P/S
- 99th
- P/B
- 97th
- P/FCF
- 99th
Bar = where today’s multiple sits in UTHR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +20.2%10Y CAGR +7.9%YoY −20.8%EPS (diluted)
5Y CAGR +19.3%10Y CAGR +8.2%YoY −20.3%Free cash flow
5Y CAGR +8.4%10Y CAGR +12.1%YoY −64.2%TTM: operating cash flow $1.4B, capex −$562.4M
Q3 2026: operating cash flow $306.5M, capex −$180.7M
Shares (diluted)
5Y +7.4%10Y −6.4%YoY −4.2%Net income
5Y CAGR +21.0%10Y CAGR +7.4%YoY −23.6%About United Therapeutics#
Data provided bySource: Twelve DataUnited Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, with particular expertise in pulmonary arterial hypertension. Its current portfolio includes Tyvaso DPI and Tyvaso inhalation solution, Remodulin injection, Orenitram extended-release tablets, and Adcirca tablets, which address different treatment needs within pulmonary vascular disease. The company also markets Unituxin, a therapy used in the treatment of high-risk neuroblastoma. United Therapeutics combines pharmaceutical research, manufacturing, regulatory operations, and specialized commercial support to serve patients, healthcare professionals, hospitals, and specialty pharmacies. Its business is centered on rare and serious diseases where ongoing treatment and differentiated delivery methods are important, including inhaled, injectable, and oral formulations. The company also operates in regenerative medicine through technologies and programs related to organ transplantation and the development of organs suitable for clinical use. United Therapeutics Corporation therefore occupies a specialized role in biotechnology, linking innovative drug development with advanced approaches to address critical shortages in transplantable organs.
Silver Spring, MD·1,400 employees·Drug Manufacturers - Specialty & Generic·unither.com·As of Oct 28, 2026
Recent filings#
- Nov 9Insider sale · PATUSKY CHRISTOPHER (Director) sold 1,210 shares for $702K at $580.00
- Nov 4Earnings · Earnings release — EPS $5.71 vs $5.85 est. (−2.4%); revenue $832.5M (+4% y/y) 1.2%
- Oct 228-K · United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
- Sep 14Insider sale · Mesa Nilda (Director) sold 228 shares for $115K at $505.79–$505.98
- Sep 88-K · United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
ETFs holding UTHR#
26 of the 193 ETFs ChartRow carries live hold UTHR. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 1.7% |
| XBI | SPDR S&P Biotech ETF | 0.9% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.6% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.6% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| COWZ | Pacer US Cash Cows 100 ETF | 0.3% |
| VB | Vanguard Small-Cap ETF | 0.3% |
| VHT | Vanguard Health Care ETF | 0.3% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
